A New Paradigm for HIV Treatment: Targeted Degradation of HIV Reverse Transcriptase via the Ubiquitin-Proteasome Pathway

HIV 治疗的新范式:通过泛素-蛋白酶体途径靶向降解 HIV 逆转录酶

基本信息

  • 批准号:
    10299633
  • 负责人:
  • 金额:
    $ 22.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-11-06 至 2023-10-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT In accordance with RFA-AI-19-072, Novel Therapeutics Directed to Intracellular HIV Targets, we propose using targeted protein degradation (TPD) against the essential HIV reverse transcriptase (RT). The RFA states “Controlling protein function by controlling intracellular protein levels has evolved as a promising and novel therapeutic strategy. This can be achieved by the targeted degradation of intracellular proteins thru the ubiquitin- proteasome pathway.” Heterobifunctional targeted protein degraders (TPDs) are being actively pursued as enhancers of proteasomal destruction of proteins specifically associated with several cancers. Such agents offer advantages over traditional occupancy-based inhibitors including a unique catalytic mechanism of action, greater target selectivity, and a reduced probability for resistance development. Surprisingly, this promising therapeutic modality has only recently been applied to antiviral drug discovery through a successful Telapravir-based TPD effective against the wild type and resistant forms of the HCV protease. Analysis of reported HIV-1 drug-bound structures suggests that the essential viral RT should be readily adaptable to targeted protein degradation. The potent and clinically used HIV-1 RT inhibitor (RTI), Rilpivirine (RPV) binds the RT site in Gag-Pol and also allosterically inhibits p66/p51 RT function by binding the non-nucleoside-RTI (NNRTI) Binding Pocket (NNIBP) on the p66 subunit. RPV is amenable to conjugation with linkers and ubiquitin E3 ligase recruiting ligands to serve in the design and preparation of prototype HIV-1 RT TPDs. The OBJECTIVE of this study is to show proof-of-concept of a new inhibitory mechanism by which HIV-1 RT can be targeted for degradation, impairing HIV infectivity and replication. Importantly, due to TPDs’ unique mechanism of action, even a low- affinity RT/TPD interaction will likely lead to effective target degradation. Thus, we pose the HYPOTHESIS that RPV-based TPDs will not only augment inhibition against HIV-1 with RTI-sensitive RT but will remain effective against RTI-resistant RT variants. Ultimately, this approach can reduce resistance development and potentially extend regimen lifetimes in the fight against HIV disease. The objective of AIM 1 is to design and prepare RPV- based TPDs built on state-of-the-art computational methods and predictive physicochemical properties currently accepted for in vivo active TPDs. In AIM 2, we will screen the two series of TPDs for antiviral activity in complementary in vitro models of HIV-1 single-round infection (in the TZM-bl assay), and of replication (in primary CD4+ T lymphocytes). The IMPACT of the discovery of targeted HIV-1 RT degraders that limit infectivity and replication through a mechanism distinct from occupancy-based HIV-1 RTIs will be the identification of agents that are effective against RTI-resistant HIV strains and that limit RTI susceptibility to viral resistance development. Grandly, this research will demonstrate that TPD approaches can be superior in the treatment of HIV disease and will set the stage for the advancement of TPDs against other HIV targets with improvements in the prevention of resistance development and with concomitant enhanced clinical treatment outcomes.
项目总结/文摘

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert C Reynolds其他文献

Robert C Reynolds的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert C Reynolds', 18)}}的其他基金

A New Paradigm for HIV Treatment: Targeted Degradation of HIV Reverse Transcriptase via the Ubiquitin-Proteasome Pathway
HIV 治疗的新范式:通过泛素-蛋白酶体途径靶向降解 HIV 逆转录酶
  • 批准号:
    10153409
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Targeting MDR-TB
针对耐多药结核病
  • 批准号:
    7831362
  • 财政年份:
    2009
  • 资助金额:
    $ 22.9万
  • 项目类别:
Targeting MDR-TB
针对耐多药结核病
  • 批准号:
    7936235
  • 财政年份:
    2009
  • 资助金额:
    $ 22.9万
  • 项目类别:
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative
用于 ML 计划的基于核苷模板的中试规模文库
  • 批准号:
    7683197
  • 财政年份:
    2008
  • 资助金额:
    $ 22.9万
  • 项目类别:
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative
用于 ML 计划的基于核苷模板的中试规模文库
  • 批准号:
    7938009
  • 财政年份:
    2008
  • 资助金额:
    $ 22.9万
  • 项目类别:
Pilot-Scale Libraries Based on Nucleoside Templates for the ML Initiative
用于 ML 计划的基于核苷模板的中试规模文库
  • 批准号:
    7556025
  • 财政年份:
    2008
  • 资助金额:
    $ 22.9万
  • 项目类别:
Crystallization of the Galactosyltransferase from Mtb
Mtb 半乳糖基转移酶的结晶
  • 批准号:
    6571603
  • 财政年份:
    2002
  • 资助金额:
    $ 22.9万
  • 项目类别:
Inhibitor of FtsZ Polymerization in M. tuberculosis
结核分枝杆菌中 FtsZ 聚合的抑制剂
  • 批准号:
    6751274
  • 财政年份:
    2002
  • 资助金额:
    $ 22.9万
  • 项目类别:
Inhibitor of FtsZ Polymerization in M. tuberculosis
结核分枝杆菌中 FtsZ 聚合的抑制剂
  • 批准号:
    6496584
  • 财政年份:
    2002
  • 资助金额:
    $ 22.9万
  • 项目类别:
Inhibitor of FtsZ Polymerization in M. tuberculosis
结核分枝杆菌中 FtsZ 聚合的抑制剂
  • 批准号:
    6627839
  • 财政年份:
    2002
  • 资助金额:
    $ 22.9万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 22.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 22.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 22.9万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 22.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了